Date: 2015-03-18
Type of information: Services contract
Compound: NBTXR3
Company: Nanobiotix (France) CordenPharma (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: services contract
Action mechanism:
Disease:
Details: * On March 18, 2015, Nanobiotix, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced it has appointed CordenPharma as its manufacturing partner. The opening of a new manufacturing line and the scaling up of production is an important step in NBTXR3’s route to commercialization. The new manufacturing line, located in France, will increase the amount of NBTXR3 product available. With an anticipated award of a CE mark in 2016, the Company is preparing to scale-up production further to meet the needs of future commercialization. Furthermore, Nanobiotix is anticipating future demand from clinical trials in the coming years in Europe and in the United States. In November 2014, Nanobiotix announced its global clinical development plan. In addition to Soft Tissue Sarcoma and Head and Neck cancer, the plan now includes metastatic liver cancer, hepatocellular carcinomas and prostate cancer. In the second half of 2015, the liver cancers and high risk prostate cancer programs are anticipated to enter the clinical stage. CordenPharma is an international full service CMO (contract manufacturing organization) which provides specialized technologies for the development and manufacture of health products. The company is recognized by EMA and FDA thanks to its eight cGMP facilities across Europe and the United States and works with both pharma and biotech companies. Its facilities are regularly inspected by the regulatory authorities (FDA and EMA) and have a good track record.
Financial terms:
Latest news:
